Effects of GnRH-a treatment on clinical features, height standard deviation (SD) for chronological age, and height SD for bone age in GDPP due to hypothalamic hamartoma
| Patient | CA at onset of GnRH-a treatment (years) | Age at treatment (years) | Baseline | Latest visit | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Tanner stage | Height SD for CA | Height SD for BA | Tanner Stage | Height SD for CA | Height SD for BA | |||||
| 1 | 1.33 | 8.4 | G2PH1 | +0.21 | +1.46 | G1PH1 | −0.47 | +1.37 | ||
| 2 | 1.91 | 3.4 | G2PH3 | +2.90 | −1.32 | G1PH2 | +2.24 | +0.60 | ||
| 3 | 2.16 | 2.8 | G2PH1 | +0.20 | +0.20 | G1PH1 | +1.09 | +0.68 | ||
| 4 | 1.16 | 3.6 | G2PH2 | +2.81 | +0.16 | G1PH1 | +3.05 | +1.59 | ||
| 51-150 | 2.5 | 5.0 | – | – | – | G4PH4 | +5.87 | −0.51 | ||
| 6 | 1.33 | 6.9 | B3PH1 | +1.04 | −0.66 | B3PH1 | +3.11 | +0.02 | ||
| 7 | 1.83 | 4.1 | B4PH3 | +3.0 | −3.71 | B3PH3 | +3.52 | +0.46 | ||
| 8 | 1.08 | 2.7 | B2PH1 | +1.04 | −2.60 | B1PH1 | +0.33 | +3.10 | ||
| Mean (SD) | 1.66 (0.51) | 4.61 (2.05) | +1.60 (1.27) | −0.92 (1.77) | +1.83 (1.54) | +1.11 (1.02) | ||||
| Range | 1.08 to 2.5 | 2.66 to 8.41 | 0.2 to 3.0 | −3.71 to 1.46 | −0.47 to 3.52 | 0.02 to 3.10 | ||||
↵1-150 Case 5 was not included in the statistical analysis; p < 0.05 (baseline height SD for bone age v latest height SD for bone age).
CA, chronological age; BA, bone age; B, breast; PH, pubic hair; G, genitalia (testicular size), according to Tanner’s criteria.